Immune Takes Road Less Traveled with Epicept Buy
By Marie Powers
Monday, August 26, 2013
Privately held Immune Pharmaceuticals Ltd. swam against the tide of biotechs rushing to initial public offerings (IPO) by completing its merger with Epicept Corp., gaining access to the public markets and an expanded pipeline of cancer and pain compounds.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.